Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent Deferred Tax AssetsCurrent Deferred Tax AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Compugen (CGEN) Cash & Equivalents (2016 - 2025)

Compugen's Cash & Equivalents history spans 17 years, with the latest figure at $90.6 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents rose 396.99% to $90.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $90.6 million, a 396.99% increase, with the full-year FY2025 number at $90.6 million, up 396.99% from a year prior.
  • Cash & Equivalents hit $90.6 million in Q4 2025 for Compugen, up from $7.5 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for CGEN hit a ceiling of $90.6 million in Q4 2025 and a floor of $6.5 million in Q2 2025.
  • Historically, Cash & Equivalents has averaged $17.2 million across 5 years, with a median of $11.1 million in 2022.
  • The widest YoY moves for Cash & Equivalents: up 396.99% in 2025, down 45.55% in 2025.
  • Tracing CGEN's Cash & Equivalents over 5 years: stood at $7.8 million in 2021, then skyrocketed by 41.76% to $11.1 million in 2022, then rose by 25.6% to $13.9 million in 2023, then surged by 31.24% to $18.2 million in 2024, then surged by 396.99% to $90.6 million in 2025.
  • Business Quant data shows Cash & Equivalents for CGEN at $90.6 million in Q4 2025, $7.5 million in Q3 2025, and $6.5 million in Q2 2025.